Treatment of prostate cancer with CD46 targeted <sup>225</sup> Ac alpha particle radioimmunotherapyAnil P. Bidkar(University of California, San Francisco), Robert R. Flavell(University of California, San Francisco)bioRxiv (Cold Spring Harbor Laboratory)October 14, 202210.1101/2022.10.13.512165Cited by 0SaveCiteExport RISWatch citationsRelated PapersDevelopment of CD46 targeted alpha theranostics in prostate cancer using <sup>134</sup>Ce/<sup>225</sup>Ac-Macropa-PEG<sub>4</sub>-YS5|Theranostics|2024|27